drugset / Trial / NCT04180774
Safety and Efficacy of Tag-7 Gene-modified Vaccine in Locally Advanced or Metastatic Malignant Melanoma or Kidney Cancer
Phase 1/2
Completed
80 enrolled
N.N. Petrov National Medical Research Center of Oncology
Institute of Gene Biology Russian Academy of Sciences · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study was designed to assess the safety and efficacy of inactivated tumor cells genetically modified with the TAG-7 gene as immunotherapy for cancer. Patients with melanoma or kidney cancer were included since they have immune-dependent tumors. Treatment was done in the adjuvant setting after complete cytoreduction of locally advanced or metastatic disease or in the therapeutic setting in patients where complete cytoreduction was impossible.
Timeline
- Start
- 2001-01-31
- Primary completion
- 2018-12-31
- Completion
- 2018-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tag-7 gene modified inactivated tumor cells | Unknown | 1e+07 cells | Subcutaneous |